NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with the University Hospital Oslo aimed at guiding treatment of patients with targeted cancer therapies.

Financial details of the agreement weren't disclosed, but New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, said that under the collaboration it will use its next-gen sequencing diagnostic platform, Neo, to identify alterations in cancer-related genes that predict a patient's response or resistance to targeted therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.